Efficient Synthesis of New Biheterocyclic 5-[(5-Trifluoromethyl-5hydroxy-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7trifluoromethylpyrazolo[1,5-*a*]pyrimidines

Alex F. C. Flores, ** Pauline F. Rosales, b Juliana L. Malavoltab and Darlene C. Flores

^aEscola de Química e Alimentos, Universidade Federal do Rio Grande, 96203-900 Rio Grande-RS, Brazil ^bDepartamento de Química, Universidade Federal de Santa Maria, 97105-900 Santa Maria-RS, Brazil

¹H and ¹³C nuclear magnetic resonance (NMR) and mass spectra for 5-[(5-trifluoromethyl-5-hydroxy-(3-substituted)-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethyl)pyrazolo[1,5-*a*] pyrimidines (**4a-l**) are shown.

The ¹H and ¹³C spectra were recorded at 298 K on a Bruker DPX 400 spectrometer (¹H at 400.13 MHz, ¹³C at 100.63 MHz) with a digital resolution of \pm 0.01 ppm. All of the chemical shifts are expressed in ppm, and ¹H and ¹³C are reported with respect to internal tetramethylsilane

(TMS). Solutions of 0.1 mol L⁻¹ CDCl₃ were used (1-4) except with compound **5**, for which 0.1 mol L⁻¹ DMSO- d_6 was used. H–H and C–F coupling constants are in Hz. Mass spectra were registered in a HP 5973 MSD connected to a HP 6890 GC and interfaced with a Pentium PC. The gas chromatograph (GC) was equipped with a split-splitless injector, auto-sampler, and cross-linked HP-5 capillary column (30 m × 0.32 mm i.d.), and helium was used as the carrier.



Figure S1. ¹H NMR spectrum (CDCl₃, 400 MHz) of methyl 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidin-5-yl)propanoate (1).



Figure S2. ¹³C NMR spectrum (CDCl₃, 100 MHz) of methyl 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)propanoate (1).



Figure S3. ¹⁹F NMR spectrum (CDCl₃, 376.4 MHz) of methyl 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)propanoate (1).



User Spectra

Figure S4. ESI mass spectra of 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidin-5-yl)propanoate (1).



Figure S5. ¹H NMR spectrum (CDCl₃, 400 MHz) of 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidin-5-yl)propanoyl hydrazide (2).



Figure S6. ¹³C NMR spectrum (CDCl₃, 100 MHz) of 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)propanoyl hydrazide (2).



Figure S7. ¹⁹F NMR spectrum (CDCl₃, 376.4 MHz) of 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)propanoyl hydrazide (2).





Figure S8. ESI mass spectrum of 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidin-5-yl)propanoyl hydrazide (2).



Figure S9. ¹H NMR spectrum (CDCl₃, 400 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4a**).



Figure S10. ¹³ C NMR spectrum (CDCl₃, 100 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4a**).



Figure S11. ESI mass spectrum of 5-[(5-trifluoromethyl-5-hydroxy-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4a**)



Figure S12. ¹H NMR spectrum (CDCl₃, 400 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-methyl-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4b**).



Figure S13. 13 C NMR spectrum (CDCl₃, 100 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-methyl-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4b**).



Figure S14. ¹⁹F NMR spectrum (CDCl₃, 376.4 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-methyl-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4b**).



Figure S15. ESI mass spectrum of 5-[(5-trifluoromethyl-5-hydroxy-3-methyl-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4b**).



Figure S16. ¹H NMR spectrum (CDCl₃, 400 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(2-methylpent-3-enyl)-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4c**).



 $\label{eq:sigma} Figure S17. {}^{13}C NMR \ spectrum \ (CDCl_3, 100 \ MHz) \ of 5-[(5-trifluoromethyl-5-hydroxy-3-(2-methylpent-3-enyl)-4,5-dihydro-1 \\ H-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidine \ (4c).$



 $\label{eq:sigma} Figure S18. HSQC spectrum (CDCl_3, 400 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(2-methylpent-3-enyl)-4, 5-dihydro-1H-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidine (4c).$



 $\label{eq:Figure S19.} Figure S19. {}^{19} F NMR spectrum (CDCl_3, 376.4 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(2-methylpent-3-enyl)-4,5-dihydro-1H-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidine (4c).$



 $\label{eq:sector} Figure S20. ESI mass spectrum of 5-[(5-trifluoromethyl-5-hydroxy-3-(2-methylpent-3-enyl)-4, 5-dihydro-1H-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidine (4c).$



Figure S21. ¹H NMR spectrum (CDCl₃, 400 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(2-phenylethyl)-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4d**).



Figure S22. ¹³C NMR spectrum (CDCl₃, 100 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(2-phenylethyl)-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4d**).



Figure S23. ¹⁹F NMR spectrum (CDCl₃, 376.4 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(2-phenylethyl)-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4d**).



Figure S24. ESI mass spectrum of 5-[(5-trifluoromethyl-5-hydroxy-3-(2-phenylethyl)-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4d**).

Figure S25. ¹H NMR spectrum (CDCl₃, 400 MHz) of methyl 3-(5-hydroxy-1-(3-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)propa noyl)-5-trifluoromethyl-4,5-dihydro-1*H*-pyrazol-3-yl)propanoate (**4e**).

Figure S26. ¹³C NMR spectrum (CDCl₃, 100 MHz) of methyl 3-(5-hydroxy-1-(3-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)propa noyl)-5-trifluoromethyl-4,5-dihydro-1*H*-pyrazol-3-yl)propanoate (**4e**).

Figure S27. ESI mass spectrum of methyl 3-(5-hydroxy-1-(3-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)propa noyl)-5-trifluoromethyl-4,5-dihydro-1*H*-pyrazol-3-yl)propanoate (**4e**).

Figure S28. ¹H NMR spectrum (CDCl₃, 400 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-phenyl-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4f**).

Figure S29. ¹H NMR spectrum (CDCl₃, 400 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-phenyl-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4f**). Expanded between 3.47-3.82 ppm.

Figure S30. ¹³C NMR spectrum (CDCl₃, 100 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-phenyl-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4f**).

Figure S31. ¹⁹F NMR spectrum (CDCl₃, 376.4 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-phenyl-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4f**).

User Spectra

x10 2

1

0.8

0.6

0.4

0.2

0

50

50

Figure S32. ESI mass spectrum 5-[(5-trifluoromethyl-5-hydroxy-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7trifluoromethylpyrazolo[1,5-a]pyrimidine (4f).

75 100 125 150 175 200 225 250 275 300 325 350 375 400 425 450 475 500 525 Counts (%) vs. Mass-to-Charge (m/z)

Figure S33. ¹H NMR spectrum (CDCl₃, 400 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(4-methylphenyl)-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidine (4g).

Figure S34. ¹³C NMR spectrum (CDCl₃, 100 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(4-methylphenyl)-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (4g).

Figure S35. HSQC spectrum (CDCl₃, 400 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(4-methylphenyl)-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (4g).

 $\label{eq:sigma} Figure S36. HMBC spectrum (CDCl_3, 400 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidine (4g).$

 $\label{eq:Figure S37. 19} F NMR spectrum (CDCl_3, 376.4 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(4-methylphenyl)-4, 5-dihydro-1H-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidine (4g).$

 $\label{eq:Figure S38. ESI mass spectrum of 5-[(5-trifluoromethyl-5-hydroxy-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidine (4g).$

Figure S39. ¹H NMR spectrum (CDCl₃, 400 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidine (4h).

Flores et al.

 $\label{eq:Figure S40.} Figure S40. {}^{13}C NMR spectrum (CDCl_3, 100 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidine (4h).$

Figure S41. HSQC spectrum (CDCl₃, 400 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidine (**4h**).

Figure S42. HMBC spectrum (CDCl₃, 400 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-(4-methoxyphenyl)-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (4h).

 $\label{eq:Figure S43. ESI mass spectrum of 5-[(5-trifluoromethyl-5-hydroxy-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidine (4h).$

Figure S44. ¹H NMR spectrum (CDCl₃, 400 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-ethoxy-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4i**).

Figure S45. 13 C NMR spectrum (CDCl₃, 100 MHz) of 5-[(5-trifluoromethyl-5-hydroxy-3-ethoxy-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4i**).

Figure S46. HSQC spectrum (CDCl₃, 400 MHz) of 5-[(3-ethoxy-5-trifluoromethyl-5-hydroxy-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4i**).

Figure S47. HMBC spectrum (CDCl₃, 400 MHz) of 5-[(3-ethoxy-5-trifluoromethyl-5-hydroxy-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4i**).

Figure S48. ${}^{19}F$ NMR spectrum (CDCl₃, 376.4 MHz) of 5-[(3-ethoxy-5-trifluoromethyl-5-hydroxy-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (4i).

Figure S49. ESI mass spectrum of 5-[(3-ethoxy-5-trifluoromethyl-5-hydroxy-4,5-dihydro-1*H*-pyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4i**).

Figure S50. ¹H NMR spectrum (CDCl₃, 400 MHz) of 5-[1-(3-hydroxy-3-trifluoromethyl-3,3a,4,5,6,7-hexahydroindazol-2-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4j**).

Figure S51. ¹³C NMR spectrum (CDCl₃, 100 MHz) of 5-[1-(3-hydroxy-3-trifluoromethyl-3,3a,4,5,6,7-hexahydroindazol-2-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4j**).

Figure S52. ESI mass spectrum of 5-[1-(3-hydroxy-3-trifluoromethyl-3,3a,4,5,6,7-hexahydroindazol-2-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4j**).

Figure S53. ¹H NMR spectrum (CDCl₃, 400 MHz) of 1-(3-hydroxy-3-trifluoromethyl-3,3a,4,5,6,7,8,9-octahydrocycloocta[c]pyrazol-2-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidine (**4k**).

Figure S54. 13 C NMR spectrum (CDCl₃, 100 MHz) of 1-(3-hydroxy-3-trifluoromethyl-3,3a,4,5,6,7,8,9-octahydrocycloocta[*c*]pyrazol-2-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4**k).

Figure S55. ESI mass spectrum of 1-(3-hydroxy-3-trifluoromethyl-3,3a,4,5,6,7,8,9-octahydrocycloocta[c]pyrazol-2-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidine (4k).

Figure S57. ¹H NMR spectrum (CDCl₃, 400 MHz) of 1-(5-trifluoromethyl-5-hydroxy-4-methyl-3-phenyl-4,5-dihydropyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4**).

Figure S58. ESI mass spectrum of of 1-(5-trifluoromethyl-5-hydroxy-4-methyl-3-phenyl-4,5-dihydropyrazol-1-yl)-1-propan-1-one-3-yl]-2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidine (**4**)

Figure S59. ¹H NMR spectrum (DMSO-d₆, 400 MHz) of 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidin-5-yl)propanoic acid.

Figure S60. ¹³C NMR spectrum (DMSO-d_s, 100 MHz) of 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidin-5-yl)propanoic acid.

User Spectra

Figure S61. ESI mass spectrum of 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidin-5-yl)propanoic acid (5).

Figure S62. IR spectrum (KBr) of 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidin-5-yl)propanoic acid (5).